Cutler Group’s ADC Therapeutics ADCT Stock Holding History

Cutler Group’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$1K	–	5292
2021 Q3	$1K	Buy	+500	New	+$12.8K	﹤0.01%	5208

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Cutler Group's ADCT Position: Q4 2023 in Review

Cutler Group sold out of ADC Therapeutics (ADCT) in Q4 2023, closing a stake of 1,400 shares — an estimated $1K sold.

Cutler Group first reported a position in ADCT in Q3 2022 and held it in 5 quarters. The position peaked at $6K in Q4 2022. 37 funds tracked by Wall St. Rank hold ADCT as of Q4 2023.

Cutler Group reported no remaining ADC Therapeutics position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 1,400 ADC Therapeutics shares in Q4 2023, an estimated $1K.
Cutler Group first reported a position in ADC Therapeutics in Q3 2022 and held it in 5 quarters.
Cutler Group's ADC Therapeutics position peaked at $6K in Q4 2022.
37 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.